Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male/female subjects from 16 years (where legally permitted and ethically accepted) or 18 years onwards suffering from epilepsy and having completed a previous study with brivaracetam as adjunctive treatment, which allowed access to this study
Subjects with POS/PGS: inpatients or outpatients with epilepsy who participated in previous brivaracetam studies / programs which allow access to the present study
Subjects with ULD: inpatients or outpatients with epilepsy who were treated with brivaracetam in previous studies / programs which allow access to the present study
Subjects for whom the Investigator believes a reasonable benefit from the long-term administration of brivaracetam may be expected
You may not be if
Severe medical, neurological and psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
Poor compliance with visit schedule or medication intake in previous brivaracetam study
Participation in any clinical study of another investigational drug or device during the study
Pregnant or lactating woman
Clareo Health | Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
